169 related articles for article (PubMed ID: 12544772)
1. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
[TBL] [Abstract][Full Text] [Related]
2. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial.
Deitcher SR; Fesen MR; Kiproff PM; Hill PA; Li X; McCluskey ER; Semba CP;
J Clin Oncol; 2002 Jan; 20(1):317-24. PubMed ID: 11773185
[TBL] [Abstract][Full Text] [Related]
4. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
[TBL] [Abstract][Full Text] [Related]
5. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
6. Alteplase for treatment of occluded peripherally inserted central catheters: safety and efficacy in 240 patients.
Ng R; Li X; Tu T; Semba CP
J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):45-9. PubMed ID: 14709686
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer.
Liu CY; Jain V; Shields AF; Heilbrun LK
J Vasc Interv Radiol; 2004 Jan; 15(1 Pt 1):39-44. PubMed ID: 14709685
[TBL] [Abstract][Full Text] [Related]
8. Alteplase for the treatment of catheter occlusion in pediatric patients.
Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
[TBL] [Abstract][Full Text] [Related]
9. Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
Terrill KR; Lemons RS; Goldsby RE
J Pediatr Hematol Oncol; 2003 Nov; 25(11):864-7. PubMed ID: 14608195
[TBL] [Abstract][Full Text] [Related]
10. Alteplase infusion versus dwell for clearance of partially occluded central venous catheters in critically ill pediatric patients.
Ragsdale CE; Oliver MR; Thompson AJ; Evans MC
Pediatr Crit Care Med; 2014 Jul; 15(6):e253-60. PubMed ID: 24751787
[TBL] [Abstract][Full Text] [Related]
11. TROPICS 1: a phase III, randomized, double-blind, placebo-controlled study of tenecteplase for restoration of function in dysfunctional central venous catheters.
Gabrail N; Sandler E; Charu V; Anas N; Lim E; Blaney M; Ashby M; Gillespie BS; Begelman SM
J Vasc Interv Radiol; 2010 Dec; 21(12):1852-8. PubMed ID: 21111365
[TBL] [Abstract][Full Text] [Related]
12. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
[TBL] [Abstract][Full Text] [Related]
13. Alteplase versus urokinase for occluded hemodialysis catheters.
Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
[TBL] [Abstract][Full Text] [Related]
14. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
Ponce D; Mendes M; Silva T; Oliveira R
Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
[TBL] [Abstract][Full Text] [Related]
15. A phase III, open-label, single-arm study of tenecteplase for restoration of function in dysfunctional central venous catheters.
Tebbi C; Costanzi J; Shulman R; Dreisbach L; Jacobs BR; Blaney M; Ashby M; Gillespie BS; Begelman SM
J Vasc Interv Radiol; 2011 Aug; 22(8):1117-23. PubMed ID: 21570873
[TBL] [Abstract][Full Text] [Related]
16. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
Pollo V; DionÃzio D; Bucuvic EM; Castro JH; Ponce D
Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
[TBL] [Abstract][Full Text] [Related]
17. Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters.
Chesler L; Feusner JH
J Pediatr Hematol Oncol; 2002 Nov; 24(8):653-6. PubMed ID: 12439038
[TBL] [Abstract][Full Text] [Related]
18. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial.
Haire WD; Deitcher SR; Mullane KM; Jaff MR; Firszt CM; Schulz GA; Schuerr DM; Schwartz LB; Mouginis TL; Barton RP
Thromb Haemost; 2004 Sep; 92(3):575-82. PubMed ID: 15351854
[TBL] [Abstract][Full Text] [Related]
19. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
Timoney JP; Malkin MG; Leone DM; Groeger JS; Heaney ML; Keefe DL; Klang M; Lucarelli CD; Muller RJ; Eng SL; Connor M; Small TN; Brown AE; Saltz LB
J Clin Oncol; 2002 Apr; 20(7):1918-22. PubMed ID: 11919252
[TBL] [Abstract][Full Text] [Related]
20. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices.
Davis SN; Vermeulen L; Banton J; Schwartz BS; Williams EC
Am J Health Syst Pharm; 2000 Jun; 57(11):1039-45. PubMed ID: 10876745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
